Apomorphine in Severe Brain-injured Patients

Disorder of Consciousness Clinical Trial

— APODoC  

Official title:

Randomized Controlled Trial of Apomorphine in Severe Brain-injured Patients: a Double-blind Behavioral and Neuroimaging Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05213169
• Other study ID #: 2017/81b
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: June 18, 2021
• Est. completion date: June 30, 2025

Study information

• Verified date: April 2023
• Source: University of Liege
• Contact: Emilie Szymkowicz, MSc.
• Phone: +32492319947
• Email: emilie.szymkowicz[@]uliege.be
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background:

Patients who survive severe brain injury may develop chronic disorders of consciousness (DoC). Treating these patients to improve recovery is extremely challenging because of scarce and inefficient therapeutical options. Among pharmacological treatments, apomorphine, a potent direct dopamine agonist, has exhibited promising behavioral effects, but its true efficacy and its mechanism remains unknown. This randomized controlled study aims to verify the effects of apomorphine subcutaneous infusion in patients with disorders of consciousness and investigate the neural networks targeted by this treatment.

Methods/design:

The double-blind randomized controlled trial will include 48 patients: 24 patients will be randomly assigned to the apomorphine and 24 to the placebo group. Investigators and the patients will be unaware of the nature of the treatment rendered.

Primary outcome will be determined as behavioral response to treatment as measured by changes of diagnosis using the Coma Recovery Scale - Revised (CRS-R), while secondary outcome measures will include the Nociception Coma Scale - Revised (NCS-R), Disability Rating Scale (DRS), Wessex Head Injury Matrix (WHIM), circadian rhythm using actimetry, electroencephalography (EEG), positron emission tomography (PET) and functional magnetic resonance imaging (fMRI). The Glasgow Outcome Scale - Extended (GOS-E) and a phone-adapted version of the CRS-R will be used for long-term follow-up.

Statistical analyses will focus on the detection of changes induced by apomorphine treatment at the individual level (comparing data before and after treatment) and at the group level (comparing responders with non-responders). Response to treatment will be measured at four different levels: 1. behavioral response (CRS-R, NCS-R, DRS, WHIM, GOS-E, phone CRS-R), 2. brain metabolism (PET), 3. network connectivity (resting-state fMRI, clinical EEG and high-density EEG) and 4. Circadian rhythm changes (actimetry, body temperature, 24h-EEG).

Discussion:

Apomorphine is a promising and safe strategy for the treatment of DoC but efficacy, profile of the responding population and underlying mechanism remain to be determined. This trial will provide unprecedented data that will allow to investigate the response to apomorphine using multimodal methods and shed new light on the brain networks targeted by this drug in terms of behavioral response, functional connectivity and metabolism.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: June 30, 2025
• Est. primary completion date: June 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• 18-80 years old.

• Clinically stable, not dependent on medical ventilators for respiration.

• Diagnosed as in an unresponsive wakefulness syndrome or minimally conscious state according to the international criteria and based on at least 2 consistent CRS-R in the last 14 days (one CRS-R in the last 7 days).

• More than 4 weeks post-insult.

• No serious neurological impairments others than related to their acquired brain injury.

• No neurological medications other than anti-epileptic or anti-spasticity drugs within the last two weeks.

• No use of dopaminergic medications other than apomorphine within the last two weeks.

• Informed consent from legal representative of the patient (if patients recover, their consent will also be obtained).

Exclusion Criteria:

• Use of dopamine agonists or antagonists (e.g. amantadine, bromocriptine, l-dopa, pramipexole, ropinirole, amphetamine, bupropion, methylphenidate / risperidone, haloperidol, chlorpromazine, flupentixol, clozapine, olanzapine, quetiapine) in the last 4 weeks or 4 half-lives of the drug.

• Use of drugs with known significant prolongation of the QT interval (e.g. class 1 antiarrythmics, sotalol, macrolides, quinolones, antipsychotic drugs, tricyclic antidepressants. Methadone, chloroquine, quinine)

• A corrected QT interval over 480ms (calculated using Bazett's formula on a standard 12-lead ECG recorded in the last 14 days) or other risk factors for arrhythmia (congestive cardiac failure, severe hepatic impairment or significant electrolyte disturbance).

• A history of previous neurological functional impairment.

• Contraindication to MRI, EEG, or PET (e.g., electronic implanted devices, active epilepsy, external ventricular drain).

• Use of nitrates or other vasodilators, central nervous system acting agents such as barbiturates, morphine and related drugs (relative exclusion criterion)

Related Conditions & MeSH terms

• Consciousness Disorders
• Disorder of Consciousness

Intervention

Drug:
• Apomorphine Hydrochloride 5mg/ml
Product administered using an external continuous subcutaneous infusion pump.

Other:
• Sodium chloride 9mg/ml
Product administered using an external continuous subcutaneous infusion pump.

Locations

Country	Name	City	State
Belgium	University of Liege	Liege
Belgium	Hôpital Valdor - ISoSL	Liège
Belgium	Centre Hospitalier Neurologique William Lennox	Ottignies-Louvain-la-Neuve
Spain	VITHAS	Valencia

Sponsors (4)

Lead Sponsor	Collaborator
University of Liege	Centre Hospitalier Neurologique William Lennox (Belgium), Hôpital Valdor - ISoSL (Belgium), VITHAS hospitales (Spain)

Countries where clinical trial is conducted

Belgium,  Spain, 

References & Publications (4)

Fridman EA, Calvar J, Bonetto M, Gamzu E, Krimchansky BZ, Meli F, Leiguarda RC, Zafonte R. Fast awakening from minimally conscious state with apomorphine. Brain Inj. 2009 Feb;23(2):172-7. doi: 10.1080/02699050802649662. — View Citation

Fridman EA, Krimchansky BZ, Bonetto M, Galperin T, Gamzu ER, Leiguarda RC, Zafonte R. Continuous subcutaneous apomorphine for severe disorders of consciousness after traumatic brain injury. Brain Inj. 2010;24(4):636-41. doi: 10.3109/02699051003610433. — View Citation

Gosseries O, Charland-Verville V, Thonnard M, Bodart O, Laureys S, Demertzi A. Amantadine, apomorphine and zolpidem in the treatment of disorders of consciousness. Curr Pharm Des. 2014;20(26):4167-84. — View Citation

Sanz LRD, Lejeune N, Blandiaux S, Bonin E, Thibaut A, Stender J, Farber NM, Zafonte RD, Schiff ND, Laureys S, Gosseries O. Treating Disorders of Consciousness With Apomorphine: Protocol for a Double-Blind Randomized Controlled Trial Using Multimodal Assessments. Front Neurol. 2019 Mar 19;10:248. doi: 10.3389/fneur.2019.00248. eCollection 2019. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline Coma Recovery Scale - Revised (CRS-R)	The CRS-R is a standardized validated neurobehavioral scale designed to assess patients with disorders of consciousness. It is divided in 6 subscales: Auditory Function (0-4 points), Visual Function (0-5 points), Motor Function (0-6 points), Oromotor/Verbal Function (0-3 points), Communication (0-2 points), Arousal (0-3 points). The subscores are summed to calculate a total score ranging from 0 to 23 points. Higher scores indicate better functions. More importantly, it provides the patient's diagnosis (coma, UWS, MCS-, MCS+, EMCS) based on the presence of specific items in different subscales (regardless of total score). Analyses will look for changes of diagnosis, changes of total score and changes of each subscore before, during and after apomorphine treatment.	up to 90 days (5 CRS-R baseline, 5 CRS-R treatment, 5 CRS-R follow-up)
Secondary	Change from Baseline Nociception Coma Scale - Revised (NCS-R)	The NCS-R is a standardized validated scale designed to assess the perception of pain in patients with disorders of consciousness unable to functionally communicate. It is divided in 3 subscales: Motor Response (0-3 points), Verbal Response (0-3 points) and Facial Expression (0-3 points). The subscores are summed to calculate a total score ranging from 0 to 9 points. Higher scores indicate a higher perception of pain. Analyses will look for changes of total score and changes of each subscore before, during and after treatment.	up to 90 days (5 NCS-R baseline, 5 NCS-R treatment, 5 NCS-R follow-up)
Secondary	Change from Baseline Disability Rating Scale (DRS)	The DRS is validated scale designed to assess disability including the impairment and handicap of patients. It is divided in 8 subscales: eye-opening (0-3 points), communication ability (0-4 points), motor response (0-5 points), feeding (0-3 points), toileting (0-3 points), grooming (0-3 points), level of functioning (0-5 points) and employability (0-3 points). The subscores are summed to calculate a total score ranging from 0 to 29 points. Higher scores indicate a higher disability. Analyses will look for changes of total score before, during and after treatment.	up to 90 days (5 DRS baseline, 5 DRS treatment, 5 DRS follow-up)
Secondary	Change from Baseline Wessex Head Injury Matrix (WHIM)	The WHIM is validated matrix designed to assess recovery in patients with disorders of consciousness. It is composed of 62 sequential items covering communication ability, cognitive skills and social interaction. The total number of achieved items and the highest achieved item are recorded. Analyses will look for changes of the total number and the highest achieved items before, during and after treatment.	up to 90 days (5 WHIM baseline, 5 WHIM treatment, 5 WHIM follow-up)
Secondary	Change from Baseline Circadian rhythm	Wrist actigraph recorded data on limb movements to calculate circadian rythmycity (measured in minutes) corresponding to the period of the biological temporal rhythms with oscillations around 24 hours.	up to 90 days (constant recording from enrollment)
Secondary	functional Magnetic Resonance Imaging (fMRI)	MRI functional connectivity using a seed-voxel approach, between regions of interest (here: striatum, globus pallidus interna, thalamus and prefrontal cortex) and the time course from all other brain voxels.	up to 90 days (fMRI before treatment initiation and after treatment completion)
Secondary	Positron Emission Tomography (PET)	Quantification of PET signal using standardized uptake values of fluorodeoxyglucose.	up to 90 days (PET before treatment initiation and after treatment completion)
Secondary	Conventional Electroencephalography (cEEG)	EEG spectral power within fixed bands or dynamic connectivity using median spectral connectivity and graph-theoretic topology metrics (clustering coefficient, path length, modularity and participation coefficient).	up to 90 days (4 cEEG baseline, 5 cEEG treatment, 5 cEEG follow-up)
Secondary	24-hour Electroencephalography (24-h EEG)	24-h EEG recordings to calculate the number of sleep cycles during day and night as well as the duration spent in each phase of sleep.	up to 90 days (24-h EEG before treatment initiation and after treatment completion)
Secondary	High-Density Electroencephalography (HD-EEG)	Multivariate classifier giving the probabilty to have signs of consciousness based on a machine-learning approach using 120 EEG markers.	up to 90 days (HD-EEG before treatment initiation and after treatment completion)
Secondary	Glasgow Outcome Scale - Extended (GOS-E)	The GOS-E is a standardized validated scale designed to assess the the functional outcome of patients with disorders of consciousness. It is a single score ranging from 1 (dead) to 8 (upper good recovery). Higher scores indicate a higher functional recovery. It will be performed remotely by telephone contact with the patient or their relatives.; Analyses will look at differences in GOS-E score between responders and non-responders to apomorphine treatment, as well as differences in time within individual patients.	from 6 months post-treatment up to 24 months post-treatment (GOS-E at 6 months,12 months and 24 months)
Secondary	Phone-adapted CRS-R	The phone-adapted CRS-R is a scale designed to assess remotely patients with disorders of consciousness. Unlike the CRS-R, it does not comprise subcores or a total score, but provides the clinical diagnosis of the patient (coma, UWS, MCS-, MCS+, EMCS) using the same diagnostic items as the CRS-R.; Analyses will look at differences in Phone-adapted CRS-R diagnosis between responders and non-responders to apomorphine treatment, as well as differences in time within individual patients.	from 6 months post-treatment up to 24 months post-treatment (phone-adapted CRS-R at 6 months,12 months and 24 months)